Moderna Inc. and the US National Institute of Allergy and Infectious Diseases (NIAID) have reported the dosing of the first patient for a novel vaccine… Read More »Moderna Inc. and the US National Institute of Allergy and Infectious Diseases (NIAID) has initiated clinical trial with an experimental vaccine for COVID19
Multiple clinical trials are now in progress aimed at developing COVID19 vaccines, repurposing drugs or new treatments running across the US, Canada, Europe and China. … Read More »A promising treatment – Remdesivir – is now progressing a clinical trial for COVID19 supported by the National Institutes of Health
The EMA (European Medicines Agency) has issued a formal statement following a comment from France’s Health Minister, Oliver Veran, suggesting that patients with COVID19 symptoms… Read More »EMA has advised that the use of ibuprofen for COVID19 treatment will be monitored.
by Dr. Gearóid Tuohy Dear EURETINA Members, COVID19 disease (“severe acute respiratory syndrome coronavirus 2” or “SARS-CoV-2”) has dominated the globe and… Read More »April 2nd, 2020: “EURETINA-Brief”© Issue No. 210
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***